November 2015 — The defendants argued that the plaintiffs in the MDL had no claim to a “failure to warn” incretin lawsuit, citing the FDA’s approval of the drugs’ labels. In ruling on the summary judgment motion, the trial judge agreed with the defendants and dismissed 749 pending cases on preemption grounds.
Reference: Battaglia, Anthony J. “In Re Incretin Mimetics Prods. Liab. Litig.” Legal Research Tools from Casetext, 13 May 2014, casetext.com/case/in-re-incretin-mimetics-prods-liab-litig-3.